Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Decreases By 53.5%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totaling 8,093 shares, a decline of 53.5% from the July 15th total of 17,399 shares. Currently, 0.6% of the company’s shares are sold short. Based on an average daily trading volume, of 14,409 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Trading of Global X Genomics & Biotechnology ETF

A number of large investors have recently modified their holdings of the company. Creative Financial Designs Inc. ADV raised its position in shares of Global X Genomics & Biotechnology ETF by 4.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after purchasing an additional 481 shares during the last quarter. C M Bidwell & Associates Ltd. purchased a new stake in shares of Global X Genomics & Biotechnology ETF in the 2nd quarter valued at $242,000. Smartleaf Asset Management LLC increased its stake in shares of Global X Genomics & Biotechnology ETF by 30.9% in the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after acquiring an additional 4,615 shares during the period. Wealth Management Partners LLC purchased a new position in shares of Global X Genomics & Biotechnology ETF during the first quarter worth $244,000. Finally, Jane Street Group LLC raised its holdings in shares of Global X Genomics & Biotechnology ETF by 7.7% during the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after purchasing an additional 10,308 shares during the last quarter. Hedge funds and other institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Trading Up 1.1%

Shares of GNOM stock traded up $0.67 during trading hours on Monday, reaching $58.98. 5,610 shares of the stock were exchanged, compared to its average volume of 15,619. The firm has a market capitalization of $86.11 million, a price-to-earnings ratio of -25.21 and a beta of 1.17. Global X Genomics & Biotechnology ETF has a 12-month low of $36.00 and a 12-month high of $59.99. The company’s 50-day moving average price is $54.86 and its 200-day moving average price is $49.06.

Global X Genomics & Biotechnology ETF Dividend Announcement

The firm also recently declared a dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 29th were paid a dividend of $0.0579 per share. The ex-dividend date of this dividend was Monday, June 29th. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is currently -27.35%.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.